In my haste to get the news out about elotuzumab's FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone
Bring it on! The FDA has approved elotuzumab (Empliciti) for use in relapsed multiple myeloma patients; the third new drug approval in three weeks! Elotuzumab was the first immunotherapy developed to fight myeloma. But unlike daratumumab, elo only works when combined with one of the established novel therapy agents in the IMiD class of drugs
We were all so excited! Dying myeloma patient, Stacy from Minnesota, responded miraculously to Mayo Clinic's experimental measles vaccine therapy. Yet apparently attempts to match this early success is fleeting. U.S. News and World Report ran an excellent update yesterday about how researchers are mobilizing patient's immune systems to fight their cancer. The ongoing Mayo
The myeloma world is all a twitter over Bristol-Myers Squibb's announcement that it will be applying for European Medicines Agency approval of the first immunotherapy, elotuzumab, for patients that have failed a single prior therapy. This would be a much broader approval than the company's FDA application here in the US. Here's the announcement part
I'm still hoping for some significant myeloma related data to emerge as the American Society of Clinical Oncology (ASCO) meetings wide down in Chicago. In the meantime, the Myeloma Beacon did a nice job reviewing several poster studies which focused on my genetic abnormality: an 11;14 translocation I developed after my first stem cell transplant.
Here is some follow-up on a more well tested anti-myeloma antibody, Elotuzumab--the kind of therapy you will find featured in my new myeloma therapies book. A number of top myeloma experts, including Doctors Jakubowiak, Jagannath, Durie and Orlowski are big fans. This article is from an online trade publication called OncLive.com: Elotuzumab Responses High in